Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4660 |
Name | indolent systemic mastocytosis |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of anatomical entity hematopoietic system disease leukocyte disease mastocytosis systemic mastocytosis indolent systemic mastocytosis |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03731260 | Phase II | Avapritinib | (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent and Smoldering Systemic Mastocytosis | Active, not recruiting | USA | SWE | NOR | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BEL | 0 |
NCT04333108 | Phase III | Masitinib | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment | Recruiting | ROU | POL | NLD | GBR | FRA | DEU | 2 |
NCT04655118 | Phase II | TL-895 | Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis | Recruiting | USA | POL | ITA | HUN | FRA | ESP | DEU | BRA | BGR | BEL | AUS | 2 |
NCT04910685 | Phase II | Elenestinib | (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | Recruiting | USA | NOR | NLD | ITA | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | 1 |
NCT05186753 | Phase II | PLX9486 | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | Recruiting | USA | POL | NOR | NLD | ITA | IRL | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 0 |